Quantcast
Viewing all articles
Browse latest Browse all 3290

Catalyst staves off Firdapse competition from Teva for a decade

Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced by the two companies. The settlement follows Florida-based Catalyst's suit ...

Viewing all articles
Browse latest Browse all 3290

Trending Articles